Effect of Individualized Catheter Management on Early Removal After Rectal Cancer Surgery
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Individualized Management Group, 24-Hour Removal Group, 48-Hour Removal Group.
- Who it may be relevant to
- Registry conditions: Urinary Catheters, Rectal Cancer, Urinary Retention. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effect of an Individualized Urinary Catheter Management Strategy on the Safety and Efficacy of Early Catheter Removal After Mid-Low Rectal Cancer Surgery: A Single-Center Randomized Controlled Trial
Overview
This study aims to systematically evaluate the safety and efficacy of different early urinary catheter removal strategies following radical resection of mid-low rectal cancer. Current clinical practice faces controversy regarding the optimal timing of catheter removal (24 hours vs. 48 hours) and lacks precise preventive measures for patients at high risk of postoperative acute urinary retention (AUR). To address these issues, this study is designed as a three-arm randomized controlled trial, directly comparing three management protocols: catheter removal at 24 hours postoperatively, catheter removal at 48 hours postoperatively, and an individualized strategy guided by a predictive model (i.e., preventive administration of tamsulosin to high-risk AUR patients prior to catheter removal). The primary endpoint is the rate of recatheterization within 7 days after the initial removal, with secondary endpoints comprehensively assessing urinary tract infections, voiding function, and postoperative complications. The ultimate goal is to provide high-quality evidence-based medical evidence to establish a precise and standardized clinical pathway for individualized postoperative catheter management.
Interventions
- Behavioral Individualized Management Group
Participants assessed by the AUR risk prediction model immediately postoperatively. High-risk patients receive prophylactic tamsulosin until catheter removal. All patients have their catheter removed at 4:00 AM on postoperative day 1. - Behavioral 24-Hour Removal Group
Participants do not receive prophylactic tamsulosin. The urinary catheter is removed uniformly at 4:00 AM on postoperative day 1. - Behavioral 48-Hour Removal Group
Participants do not receive prophylactic tamsulosin. The urinary catheter is removed uniformly at 4:00 AM on postoperative day 2.
Primary outcome measures
- Rate of recatheterization within 7 days after the initial catheter removal [Time frame: Rate of recatheterization within 7 days after the initial catheter removal]
Secondary outcome measures (5)
- Incidence of Catheter-Associated Urinary Tract Infection (CAUTI). [Time frame: within 1 days after the initial catheter removal]
- Time to First Successful Voiding after Catheter Removal [Time frame: within 1 days after the initial catheter removal]
- Voiding function assessed by the ICIQ-SF questionnaires after catheter removal [Time frame: within 2 days after the initial catheter removal]
- Voiding function assessed by the lPSS questionnaires after catheter removal [Time frame: within 2 days after the initial catheter removal]
- Incidence, types, and severity (graded by Clavien-Dindo classification) of postoperative complications within 30 days. [Time frame: within 30 days postoperatively]
Eligibility criteria
Inclusion criteria
- Patients with a preoperative pathological confirmation of rectal malignant tumor.
- Preoperative colorectal CT or rectal MRI confirming that the lower edge of the tumor is located in the rectum within 10 cm from the anal verge (including rectal and anal canal lesions).
- Patients scheduled to undergo laparoscopic or robot-assisted radical total mesorectal excision (TME).
Exclusion criteria
- History of previous abdominal surgery involving the rectum/sigmoid colon/left colon, bladder resection or partial resection, prostate surgery (in males), or hysterectomy (in females).
- History of urethral trauma, intracranial surgery, spinal surgery, cerebral infarction with limb dysfunction, or Parkinson's disease.
- Inability to void urethrally preoperatively due to any reason (e.g., ureteral puncture, ureterostomy).
- Previously diagnosed overactive bladder syndrome, prior AUR or voiding dysfunction, or diabetic cystopathy.
- Preoperative assessment indicating potential need for combined resection of other pelvic organs during surgery, including the bladder, prostate, uterus and cervix, or vagina (excluding simple adnexectomy in females).
- Preoperative assessment indicating potential need for lateral pelvic lymph node dissection.
- Preoperative renal insufficiency (serum creatinine level >133 μmol/L).
- Patients undergoing emergency surgery.
- Male patients with preoperative benign prostatic hyperplasia requiring medication.
- Presence of indwelling ureteral stents, ureteral stenosis, or bilateral hydronephrosis.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- The First Hospital of Jilin University — Changchun
Identifiers
NCT: NCT07346586 · ICCAUT-3